Urothelial Carcinoma

September 02, 2021

Tecentriq and Keytruda may also be eventually approved as adjuvant therapies.

September 01, 2021

Developers of the drug express disappointment but plan to seek meetings with regulators in hopes of reviving the application.

August 31, 2021

Mobile devices for patients to report symptoms associated with immune checkpoint inhibitors address an unmet need.

August 12, 2021

At this time, two of three conferences have been reverted to a in-person and virtual format. This includes The American Urological Association (AUA) 2021 Annual Meeting and the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting.

August 03, 2021

The Society for Immunotherapy of Cancer (SITC) released guidelines based on FDA approved immune checkpoint inhibitors (ICIs) for the treatment of urothelial cancer arising from the bladder and other areas of the urinary tract. The guidelines were based around therapies such as the programmed cell death protein 1 (PD-1) inhibitors Opdivo (nivolumab) and Keytruda (pembrolizumab) and the programmed cell death ligand 1 (PD-L1) inhibitors, Tecentriq (atezolizumab), Bavencio (avelumab) and Imfinzi (durvalumab).

July 06, 2021

According to the American Urological Association, 72.5% of urologists used Advanced Practice Providers in their practice and these healthcare providers performed a variety of procedures such as a cystoscopy (procedure examining bladder lining), which assists in the diagnosis of bladder cancer. Evidence shows patients have demonstrated a growing acceptance of APPs in urology practice settings.

July 05, 2021

Researchers identified being Black and of the female gender as the strongest predictors of late-stage diagnosis.

June 30, 2021

Results suggest potential for better use of precision medicine approaches.

June 28, 2021

A presentation at the 2021 American Society of Clinical Oncology meeting earlier this month reviewed recent findings from trials investigating the treatment of urothelial cancer.

June 14, 2021

A large proportion of patients with muscle-invasive bladder cancer responded to transurethral resection of bladder tumor and a drug cocktail that included gemcitabine, cisplatin and Opdivo (nivolumab).